Board of Trustees of The Leland Stanford Junior University bought a new position in shares of CeriBell (NASDAQ:CBLL - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 623,751 shares of the company's stock, valued at approximately $16,143,000. CeriBell accounts for 1.4% of Board of Trustees of The Leland Stanford Junior University's portfolio, making the stock its 7th largest position. Board of Trustees of The Leland Stanford Junior University owned about 1.74% of CeriBell at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in the company. Legal & General Group Plc purchased a new stake in shares of CeriBell in the 4th quarter worth approximately $32,000. PNC Financial Services Group Inc. bought a new stake in CeriBell in the fourth quarter worth $47,000. Corebridge Financial Inc. purchased a new stake in shares of CeriBell in the fourth quarter worth $158,000. Wells Fargo & Company MN bought a new position in shares of CeriBell during the fourth quarter valued at $167,000. Finally, Invesco Ltd. purchased a new position in shares of CeriBell in the 4th quarter worth about $252,000.
Wall Street Analyst Weigh In
CBLL has been the subject of a number of analyst reports. Canaccord Genuity Group restated a "buy" rating and set a $33.00 price objective on shares of CeriBell in a research note on Wednesday, February 26th. LADENBURG THALM/SH SH began coverage on shares of CeriBell in a research report on Friday, April 4th. They set a "buy" rating and a $32.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $32.50.
Check Out Our Latest Stock Analysis on CeriBell
CeriBell Stock Performance
NASDAQ:CBLL traded down $0.31 during mid-day trading on Tuesday, reaching $14.57. The company's stock had a trading volume of 250,201 shares, compared to its average volume of 265,985. The firm's fifty day simple moving average is $20.72. CeriBell has a 12-month low of $10.01 and a 12-month high of $32.75.
CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The firm had revenue of $18.53 million for the quarter, compared to analysts' expectations of $17.55 million. As a group, research analysts predict that CeriBell will post -2.46 earnings per share for the current year.
About CeriBell
(
Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Recommended Stories
Before you consider CeriBell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CeriBell wasn't on the list.
While CeriBell currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
